Hexarelin Research Guide: GHS-R1a and CD36 Mechanism, Preclinical Literature, and Verification

Most growth-hormone-axis peptides are studied for a single job: engage a receptor on the pituitary and raise growth hormone output. Hexarelin is unusual because it does two distinct things through two distinct receptors. It is one of the most potent peptide growth hormone secretagogues ever characterized, acting at the same receptor as ghrelin — and it also binds a second, unrelated receptor expressed in cardiac and vascular tissue, giving it a body of preclinical cardiac literature that is largely independent of its growth hormone activity. That dual profile makes hexarelin a genuinely interesting reference compound for a research library built around the somatotropic axis and the ghrelin/GHS-R1a system. This guide surveys hexarelin at the molecular and preclinical level: what it is, how it engages its two receptors, what the primary literature actually reports, and how a research group should evaluate the material it sources.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes.

Section 1 — Molecular Profile

Hexarelin is a fully synthetic hexapeptide — six amino acids — designed as a stabilized analog of the earlier growth hormone-releasing peptide GHRP-6. Its defining structural feature is the substitution of tryptophan with 2-methyl-tryptophan at the second position, a modification that improves metabolic stability and receptor potency relative to its parent.

Hexarelin

• CAS number: 140703-51-1
• Molecular formula: C47H58N12O6
• Molecular weight: approximately 887.04 g/mol (887 Da)
• Length: 6 amino acids (hexapeptide)
• Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 (His-D-Mrp-Ala-Trp-D-Phe-Lys-NH2)
• Class: synthetic growth hormone secretagogue; peptidyl ghrelin-receptor (GHS-R1a) agonist; CD36 ligand

Two design choices define the molecule. First, the 2-methyl-tryptophan substitution sterically shields a bond that would otherwise be a target for peptidase cleavage, giving hexarelin greater stability than GHRP-6 while preserving the pharmacophore that engages the growth hormone secretagogue receptor. Second, the C-terminal amide (the “-NH2” at the end of the sequence) removes the free carboxyl group, a common stabilizing feature in secretagogue peptides. The presence of two D-amino acids — D-2-methyl-Trp and D-Phe — is also notable: substituting the naturally occurring L-form for the mirror-image D-form is a classic strategy for making a short peptide more resistant to the enzymes that recognize native L-peptide bonds. For a laboratory, these features matter as much for handling and assay reproducibility as for any downstream question.

Section 2 — Mechanism

Hexarelin’s mechanism is best described at the level of its two receptors, because it is the two-receptor profile that distinguishes it from single-target GH-axis peptides.

The first and primary receptor is the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same G-protein-coupled receptor that the endogenous hormone ghrelin activates. Hexarelin is a synthetic ghrelin-receptor agonist. On binding, GHS-R1a couples preferentially to the Gq/11 class of G-proteins, activating phospholipase C, generating inositol trisphosphate, and driving a rise in intracellular calcium in the somatotroph cells of the anterior pituitary. That calcium signal is the proximate trigger for growth hormone secretion. Mechanistic work in rats established that hexarelin’s stimulation of GH release is not a single-site event: it is attributed to a direct action on the pituitary of relatively minor importance, an indirect action involving release of growth hormone-releasing hormone (GHRH), and a contribution from an as-yet-incompletely-defined hypothalamic factor. Importantly, secretagogues like hexarelin work by a route distinct from GHRH itself and also functionally oppose the inhibitory tone of somatostatin — so they engage the axis at a different node than a GHRH analog such as sermorelin or tesamorelin.

The second receptor is CD36, a multifunctional scavenger receptor expressed on cardiomyocytes and microvascular endothelial cells. This is where hexarelin departs from most of its peptide relatives. Affinity-purification work identified CD36 as a binding partner for growth hormone-releasing peptides in cardiac tissue, and this interaction is thought to mediate a set of cardiovascular effects in model systems that are separable from — and do not depend on — systemic growth hormone release. In other words, hexarelin can act at the heart through CD36 whether or not it is raising GH through GHS-R1a.

For research design, the practical takeaways are these. Hexarelin is a ghrelin-receptor agonist, useful as a peptidyl reference ligand for the Gq/calcium arm of GHS-R1a pharmacology, distinct from the Gαs/cAMP GHRH-receptor route. And its CD36 activity means it is studied as a probe of a growth-hormone-independent signaling pathway in cardiac and vascular model systems. Everything in this article stays at exactly that level: receptor binding, second-messenger generation, and cell- and tissue-model responses.

Section 3 — Preclinical Research Data

The preclinical dataset around hexarelin clusters into two themes that mirror its two receptors.

On the growth hormone side, the foundational pharmacology characterized hexarelin as a highly active GH-releasing hexapeptide in both infant and adult rats, work that established the potency conferred by the 2-methyl-tryptophan substitution and framed hexarelin as a leading member of the synthetic secretagogue class. Follow-on mechanistic studies dissected where in the hypothalamic-pituitary axis that activity originates, distinguishing the direct pituitary component from the GHRH-mediated and hypothalamic-factor components described above.

On the cardiac side — the more distinctive body of work — hexarelin has been examined repeatedly in isolated-tissue and whole-animal injury models. In an isolated rat heart preparation, hexarelin protected against the ventricular dysfunction produced by calcium-free perfusion, an early signal that its cardiac actions were direct and separable from GH. In rodent myocardial-infarction models, hexarelin treatment was reported to improve cardiac function following experimentally induced infarction, and later work in a mouse acute-myocardial-infarction model described preserved myocardial function together with reduced cardiac fibrosis. Cell-level studies showed that both ghrelin and hexarelin stimulated proliferation of H9c2 cardiomyocytes in a dose-dependent manner, providing an in-vitro correlate for the tissue findings. More recent mechanistic reports have probed specific intracellular pathways, including modulation of the phosphatase PTEN in a coronary-artery-ligation heart-failure model and an interleukin-1 signaling contribution to protection against ischemia/reperfusion injury in rat cardiomyocytes. Additional work in streptozotocin-induced diabetic rats reported improvement in cardiomyocyte function after hexarelin treatment, extending the model set beyond ischemic injury.

Across these datasets the recurring research themes are potency and receptor duality: hexarelin’s stabilized structure is what makes it a strong GHS-R1a agonist, and its CD36 binding is what gives it a cardiac-model literature that most GH-axis peptides simply do not have. All of the outcomes above are cell-model and animal-model findings, cited here as preclinical research context only.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for a hexarelin research library:

• Deghenghi R, et al. “GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats.” Life Sciences, 1994 (PMID 7910650).
• Bodart V, et al. “CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart.” Circulation Research, 2002 (PMID 11988484).
• “Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation.” Journal of Endocrinology, 2002 (PMID 12379504).
• “Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.” 2000 (PMID 10887041).
• “The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction.” 2000 (PMID 10614623).
• “The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.” Frontiers in Physiology, 2017 (PMID 28321024).
• “Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction.” 2018 (PMC5949285).
• “Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.” 2020 (PMC7018219).

These references trace hexarelin from its original GH-releasing characterization, through the identification of CD36 as its cardiac binding partner, to the cell- and animal-model studies that define its two-receptor research profile — the primary literature a research group needs to design and interpret in-vitro work.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, hexarelin is studied for a set of overlapping, model-system purposes:

• GHS-R1a agonist reference ligand: calcium-flux, inositol-phosphate, and reporter assays in ghrelin-receptor-expressing cell lines, using hexarelin as a stabilized peptidyl comparator against ghrelin and against the parent peptide GHRP-6.
• CD36 pathway probe: cardiomyocyte and endothelial model systems used to study growth-hormone-independent signaling through the CD36 scavenger receptor, isolating cardiac responses from pituitary GH release.
• Receptor-selectivity work: contrasting the Gq/calcium GHS-R1a route that hexarelin engages with the Gαs/cAMP GHRH-receptor route engaged by GHRH analogs, making hexarelin a useful counterpart ligand for mapping GH-axis pharmacology.
• Peptide-stability studies: using the 2-methyl-tryptophan substitution, the D-amino-acid residues, and the C-terminal amide as a structural case study in how targeted modifications confer peptidase resistance, benchmarked against unmodified GHRP-6.
• Analytical method development: hexarelin and its GHRP-family relatives cluster in sequence and mass, making them demanding test articles for validating LC-MS identity workflows and HPLC separation of closely related secretagogue peptides.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade hexarelin is supplied as a research chemical rather than a finished pharmaceutical preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage figure — important even for a short hexapeptide, where deletion and diastereomer impurities can arise from the D-amino-acid and 2-methyl-tryptophan chemistry.
• LC-MS or MS identity confirmation of the ~887 Da target mass, essential in a family where the GHRP-class secretagogues cluster closely in mass and the 2-methyl substitution must be confirmed rather than assumed.
• Endotoxin and heavy-metal testing for lyophilized material intended for cell-based work.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, hexarelin is a relatively demanding synthesis — the 2-methyl-tryptophan building block and the two D-amino-acid residues are non-trivial to incorporate at high purity — so genuine research-grade material with full analytical backing carries a corresponding cost. But price alone says nothing about identity or purity; only third-party analytical data does. A low price attached to no verifiable COA is a red flag, not a bargain, and the risk of an under-characterized or mis-synthesized product is real for a modified peptide like this one.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a modified hexapeptide like hexarelin, orthogonal identity testing is not optional. It is the only way to confirm that a vial labeled as hexarelin contains the correct sequence carrying its 2-methyl-tryptophan substitution and its D-amino-acid residues — rather than a truncated deletion sequence, an unmodified GHRP-6 analog, or a diastereomer that shares part of its mass. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/hexarelin/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.